Bevacizumab Rejected By NICE In Draft Guidance Due To Uncertain Evidence Base
 

In draft guidance issued today (9 July) by the National Institute for Health and Clinical Excellence (NICE), the drug bevacizumab (Avastin, Roche Products) is not recommended for use in combination with a taxane for patients whose breast cancer has spread to other parts of the body...

More...